Related Experiment Video
Updated: May 21, 2026
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
The translation inhibitor pateamine A prevents cachexia-induced muscle wasting in mice
Sergio Di Marco1, Anne Cammas, Xian Jin Lian
1Department of Biochemistry, Rosalind and Morris Goodman Cancer Center, McGill University, 3655 Promenade Sir William Osler, Montreal, Quebec, Canada.
Abstract:
Cachexia, or muscle-wasting syndrome, is one of the major causes of death in patients affected by diseases such as cancer, AIDS and sepsis. However, no effective anti-cachectic treatment is currently available. Here we show that a low dose of pateamine A, an inhibitor of translation initiation, prevents muscle wasting caused by the cytokines interferon γ and tumour necrosis factor α or by C26-adenocarcinoma tumours. Surprisingly, although high doses of pateamine A abrogate general translation, low doses selectively inhibit the expression of pro-cachectic factors such as inducible nitric oxide synthase. This selectivity depends on the 5'UTR of inducible nitric oxide synthase messenger RNA (mRNA) that, unlike the 5'UTR of MyoD mRNA, promotes the recruitment of inducible nitric oxide synthase mRNA to stress granules, where its translation is repressed. Collectively, our data provide a proof of principle that nontoxic doses of compounds such as pateamine A could be used as novel drugs to combat cachexia-induced muscle wasting.
Insights
Low-dose pateamine A, a translation inhibitor, effectively prevents muscle wasting in cachexia. This novel approach selectively targets pro-cachectic factors, offering a potential new treatment for this debilitating condition.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Cachexia, a severe muscle-wasting syndrome, is a major cause of mortality in diseases like cancer and AIDS.
- Current treatments for cachexia are ineffective, highlighting an urgent need for novel therapeutic strategies.
Purpose of the Study:
- To investigate the potential of pateamine A as an anti-cachectic agent.
- To elucidate the mechanism by which pateamine A affects muscle wasting at the molecular level.
Main Methods:
- Administration of low-dose pateamine A to models of cachexia induced by cytokines (interferon γ, tumor necrosis factor α) and C26-adenocarcinoma tumors.
- Analysis of protein translation inhibition and selective expression of pro-cachectic factors.
- Investigation of the role of the 5' untranslated region (5'UTR) of inducible nitric oxide synthase (iNOS) mRNA and stress granule formation.
Main Results:
- Low-dose pateamine A prevented muscle wasting in various cachexia models.
- Selective inhibition of pro-cachectic factors, including inducible nitric oxide synthase (iNOS), was observed at low doses, while high doses broadly inhibited translation.
- The 5'UTR of iNOS mRNA was identified as crucial for its recruitment to stress granules and translational repression, distinguishing it from MyoD mRNA.
Conclusions:
- Pateamine A demonstrates a proof of principle for a novel therapeutic approach against cachexia-induced muscle wasting.
- Nontoxic doses of pateamine A selectively target the translation of detrimental proteins, offering a promising avenue for drug development.
- Understanding the role of mRNA 5'UTRs in translational control provides insights into targeted therapeutic interventions for cachexia.
